Solvonis Therapeutics
AUD franchise | SVN-001

Ketamine plus relapse-prevention therapy for severe alcohol use disorder

SVN-001 is in a UK Phase 3 trial, building on a published Phase 2a/b proof of concept. It is the most advanced programme in the Solvonis AUD franchise.

Phase 3 | UK, recruiting MoU signed to assess Portuguese sites

SVN-001 is investigational. It has not been approved by any regulator, and its safety and efficacy have not been established.

Product
Ketamine IV plus proprietary in-clinic relapse-prevention therapy
Patient
Severe AUD
Treatment
Three IV ketamine sessions plus in-clinic relapse-prevention therapy
Status
UK Phase 3 ongoing; MoU signed to assess Portuguese trial sites
Regulatory
Full mixed application strategy
Mechanism of action Phase 2a/b results Heavy drinking days Phase 3 design Europe References
Mechanism of action

How ketamine-based treatment works: it opens a window of plasticity, and psychosocial support is designed to work inside it

From NMDA block to new learning
01
Blocks NMDA receptors on inhibitory interneurons
Releases the brake on excitatory neurones: a transient surge of glutamate.
02
Activates AMPA receptors and BDNF–mTOR signalling
The glutamate surge switches on the pathways that drive synaptic plasticity.
03
Builds new synaptic connections
New synaptic proteins, dendritic spines and stronger excitatory synapses form in the prefrontal cortex.
04
Opens a window of plasticity
The cue–reward associations that maintain addiction become more open to change.
What this means in AUD
Stronger prefrontal control over limbic urges and cravings
Weakening of drug memories
Reported in hazardous drinkers when ketamine follows memory retrieval (Das et al., 2019).
Lower negative affect
Through ketamine’s rapid antidepressant effect.
The combination

Ketamine opens the window; in-clinic relapse-prevention therapy uses it to build healthier responses to urges, triggers and relapse risk. The integrated treatment addresses both the biological and psychosocial dimensions of severe AUD. In SVN-002, at-home digital psychosocial support is designed to play the same role.

Sources: Das et al., Nat Commun 2019;10:5187; Grabski et al., Am J Psychiatry 2022;179(2):152–162. The mechanism summarises current understanding of ketamine pharmacology; the pathway in AUD remains under investigation. NMDA: N-methyl-D-aspartate; AMPA: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BDNF: brain-derived neurotrophic factor; mTOR: mammalian target of rapamycin. Esketamine, the active ingredient of SVN-002, is the S-enantiomer of ketamine and acts at the same NMDA receptor.

Phase 2a/b trial, as published

A completed, academic-led, investigator-initiated trial in 96 patients with severe AUD

Academic investigators at two UK sites (Exeter and London) ran the trial, funded by the Medical Research Council. It was a proof of concept, not designed for registration. Solvonis is now progressing SVN-001 in Phase 3.

Four arms, 96 patients
With therapy
With alcohol education
Ketamine 0.8 mg/kg IV
Ketamine + therapy
n=24
Ketamine + education
n=24
Placebo (saline IV)
Placebo + therapy
n=23
Placebo + education
n=25

Adults with severe AUD, recently detoxified and abstinent at entry, randomised 1:1:1:1 (166 screened).

Treatment

Three 40-minute IV infusions, 1 to 3 weeks apart: ketamine 0.8 mg/kg or saline. Seven 1.5-hour sessions of relapse-prevention therapy or alcohol education, timed around each infusion. Follow-up to six months.

Endpoints at six months
1 Percentage of days abstinent: days with no alcohol (self-reported, Timeline Followback)
2 Confirmed relapse: one or more heavy drinking days (more than 64.8 g a day for men, 52.0 g for women)
Primary comparison: ketamine versus placebo, pooled across therapy arms.

What was published: one of two co-primary endpoints met, with more days abstinent on ketamine

One of the two co-primary endpoints was met.

Ketamine
Placebo (saline)
Phase 3The two regimens Phase 3 tests
Endpoint 1: days abstinent
Percentage of days over six months; higher is better
Ketamine + therapy Phase 3
n=24
86.4%
Ketamine + education
n=24
82.5%
Placebo + therapy
n=23
78.3%
Placebo + education Phase 3
n=25
70.7%
Endpoint 2: confirmed relapse
Percentage of patients at six months; lower is better
Ketamine + therapy Phase 3
n=24
62% 13/21
Ketamine + education
n=24
68% 15/22
Placebo + therapy
n=23
67% 14/21
Placebo + education Phase 3
n=25
78% 18/23
0
serious adverse events associated with the study drug (n=96). Most events were mild; there were 4 severe events in 3 participants, all on active drug.

Source: Grabski et al., Am J Psychiatry 2022;179(2):152–162 (design, funding statement, Figures 1 and 2; Table 2; Table S1). The co-primary analysis compared all ketamine with all placebo patients: days abstinent was met; confirmed relapse was not. The trial was not powered for arm-by-arm comparison. Trial name: KARE (Ketamine for Reduction of Alcohol Relapse); NCT02649231, EudraCT 2015-000222-11; recruitment September 2016 to July 2019. 96 adults, 2×2 design; arm means over six months, observed data; reporting time capped at 180 days. Confirmed relapse = one or more heavy drinking days within 180 days (n/N shown; only patients with at least 159 days of data). Pooled comparisons are ketamine versus placebo; the trial was not powered for arm-by-arm comparison or to separate drug and therapy effects.

Heavy drinking days | post hoc analysis

The same two arms on heavy drinking days (the Phase 3 primary endpoint): 55% fewer over the last two months; post hoc

Weeks 17–24, ketamine plus therapy versus placebo plus education: 0.71 vs 1.55 heavy drinking days a week (10.1% vs 22.2% of days); P=.062. Weeks 17–20 alone: 67% fewer, P=.018. Phase 3 uses these two regimens; its control receives low-dose ketamine, not saline.

Heavy drinking days, % of days
Ketamine + therapy
Placebo + education
Weeks 17–20
67% fewer | P=.018
7.3%
22.2%
Weeks 21–24
P=.226, not significant
13.0%
22.0%
Weeks 17–24 pooled
55% fewer | P=.062, not significant
10.1%
22.2%
What counts as a heavy drinking day

Phase 3 (European Medicines Agency, EMA): over 60 g of alcohol in a day for men, 40 g for women.

Phase 2a/b re-analysis: 70 g (men) and 56 g (women).

Why it matters

The EMA lists reduction in heavy drinking days as a primary variable. It is the Phase 3 primary endpoint, tested prospectively over 180 days. These Phase 2a/b figures are post hoc.

Ketamine plus therapy versus placebo plus education: further measures

Measure
Result
Status
% days abstinent, 6 months (secondary comparison, as published)
Result+15.9 points (95% CI 3.8 to 28.1)
StatusSignificant
Confirmed relapse, 6 months (secondary comparison, as published)
Result62% (13/21) vs 78% (18/23); OR 0.46 (0.12 to 1.74)
StatusNot significant
Confirmed relapse, 3 months (as published)
Result57% (12/21) vs 71% (17/24)
StatusDescriptive
Days abstinent, weeks 17–20 (post hoc)
Result79.1% vs 58.5%; +20.6 points (1.1 to 40.0)
StatusP=.039 (post hoc)
No heavy drinking days, weeks 21–24 (post hoc)
Result50.0% vs 26.1%; OR 2.83 (0.79 to 10.17)
StatusP=.127, not significant (post hoc)

Sources: Morgan CJA, Nutt DJ, medRxiv, 28 September 2026 (post hoc secondary analysis of the Phase 2a/b trial; not peer-reviewed; nominal unadjusted P values; observed cases; ketamine plus therapy n=20 vs placebo plus education n=23). Professor Nutt is Solvonis’ Chief Scientific Officer. Patients had completed detoxification and were measured 4–6 months after the last infusion. Published comparisons: Grabski et al., Am J Psychiatry 2022 (ketamine plus therapy n=24 vs placebo plus education n=25). EMA, Guideline on the development of medicinal products for the treatment of alcohol dependence, section 4.2.1. Definitions differ: EMA over 60 g (men) and 40 g (women); Grabski et al. relapse over 64.8 g and 52.0 g; Morgan and Nutt heavy drinking days 70 g and 56 g.

Phase 3 | MORE-KARE

Phase 3 tests the same two treatment regimens on the endpoint the EMA recognises

The trial is sponsored by the University of Exeter and co-funded by the National Institute for Health and Care Research (NIHR), the Medical Research Council (MRC) and Solvonis. It is authorised by the MHRA, and has been granted an Innovation Passport under the MHRA’s Innovative Licensing and Access Pathway (ILAP).

280
planned participants
Two arms
Double-blind
UK NHS sites
EU sites proposed
Primary endpoint
Heavy drinking days over 180 days
Arm 1
Ketamine 0.8 mg/kg plus relapse-prevention therapy

The most intensive Phase 2a/b arm.

Arm 2 (control)
Ketamine 0.05 mg/kg plus alcohol education

The least intensive Phase 2a/b arm. Low-dose ketamine replaces saline as an active control that protects the blind.

From the published Phase 2a/b to Phase 3

Published Phase 2a/b
Phase 3
Run by
Published Phase 2a/bAcademic investigators at two UK sites; Medical Research Council funded
Phase 3Exeter-sponsored; co-funded by NIHR, MRC and Solvonis; MHRA-authorised
Question
Published Phase 2a/bProof of concept: does ketamine increase abstinence?
Phase 3Does ketamine plus relapse-prevention therapy reduce heavy drinking days compared with control?
Comparison
Published Phase 2a/bFour arms; ketamine versus placebo pooled across therapy arms
Phase 3Two arms: ketamine 0.8 mg/kg plus relapse-prevention therapy (the Phase 2a/b’s most intensive arm) versus ketamine 0.05 mg/kg plus alcohol education
Primary endpoint
Published Phase 2a/bPercentage of days abstinent; confirmed relapse (one or more heavy drinking days)
Phase 3Heavy drinking days over 180 days
EMA guideline
Published Phase 2a/bNeither is an EMA primary variable
Phase 3Heavy drinking days is an EMA primary variable for reduction in drinking (more than 60 g a day for men, 40 g for women)
Patients
Published Phase 2a/b96 (23 to 25 per arm)
Phase 3280 planned

Sources: MORE-KARE protocol version 9, 12 March 2025 (IRAS 1008179; ISRCTN85955128); MHRA clinical trial authorisation and HRA/REC approval, 2 November 2023; MHRA ILAP Innovation Passport; Solvonis RNS, 13 October 2026; Grabski et al., Am J Psychiatry 2022;179(2):152–162; EMA, Guideline on the development of medicinal products for the treatment of alcohol dependence, section 4.2.1 (2010); Company information. “EMA primary variable” refers to the primary variables the guideline specifies for each treatment goal.

Europe

Planned European expansion of the Phase 3

On 13 October 2026, Solvonis announced a memorandum of understanding (MoU) with ICAD, Portugal’s public addiction institute, and clinical partner Panegreen, to assess adding Portuguese trial sites to MORE-KARE, the UK Phase 3 trial of SVN-001 for severe alcohol use disorder.

The MoU does not create a binding commitment to proceed with Portuguese trial participation. Any participation remains subject to sponsor and funder agreement and the required approvals.

Why heavy drinking days matter in the EU

The EMA’s guideline on alcohol dependence lists reduction in heavy drinking days (over 60 g a day for men, over 40 g for women) as a primary variable. The Phase 3 primary endpoint is the number of heavy drinking days over 180 days, using the EMA thresholds.

Proposed EU sites are intended to generate EU data on that endpoint, to support potential UK and EU marketing authorisation applications after readout.

References and disclosures
Grabski M, McAndrew A, Lawn W, et al. “Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.” Am J Psychiatry. 2022;179(2):152–162. doi:10.1176/appi.ajp.2021.21030277.
Awakn Life Sciences. KARE Phase II A/B Results: Ketamine for the Reduction of Alcoholic Relapse. January 2022.
Morgan CJA, Nutt DJ. “No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial.” medRxiv. Posted 28 September 2026. doi:10.64898/2026.09.26.26363761. Not peer-reviewed.
Das RK, et al. “Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories.” Nat Commun. 2019;10:5187. doi:10.1038/s41467-019-13162-w.
MORE-KARE Phase 3 protocol, version 9, 12 March 2025 (University of Exeter; IRAS 1008179; ISRCTN85955128). MHRA CTA 28465/0006/001-0001 and HRA and REC (23/LO/0800) approval, 2 November 2023; MHRA ILAP Innovation Passport.
Solvonis SVN-001 treatment protocol, June 2026. Company data on file.
Solvonis Therapeutics plc. MOU Reached with ICAD. RNS, 13 October 2026.
European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence, section 4.2.1 (2010).
Author disclosures (Morgan and Nutt preprint): D. Nutt is Chief Scientific Officer of, and a shareholder in, Solvonis Therapeutics. C. Morgan receives arms-length funding from Solvonis Therapeutics for the NIHR-funded MORE-KARE trial and has consulted for Solvonis Therapeutics and Eli Lilly.
“Company data on file” refers to non-public regulatory correspondence, study reports, protocols or analyses retained by Solvonis.

The same approach, built for the U.S.: SVN-002 brings an esketamine oral thin film (OTF) to moderate-to-severe AUD

See SVN-002